IGF1 and benign prostatic hyperplasia: The latest multi-cohort meta-analyses and case-control studies indicate that IGF-I can not only distinguish prostate cancer patients from those with benign prostatic hyperplasia and normal individuals, but also further distinguish high Gleason grade (aggressive) tumors from indolent tumors (2, 15).